6/13/2024  7:10:29 PM Chg. -0.3800 Volume Bid7:17:53 PM Ask7:17:53 PM Market Capitalization Dividend Y. P/E Ratio
8.5950EUR -4.23% 8,541
Turnover: 73,114.0550
8.5050Bid Size: 588 8.6250Ask Size: 588 1.48 bill.EUR - -

Business description

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease.
 

Management board & Supervisory board

CEO
Dr. Werner Lanthaler
Management board
Laetitia Rouxel, Dr. Cord Dohrmann, Dr. Craig Johnstone, Dr. Matthias Evers
Supervisory board
Prof. Dr. Iris Löw-Friedrich, Dr. Constanze Ulmer-Eilfort, Dr. Elaine Sullivan, Dr. Mario Polywka, Roland Sackers, Camilla Macapili Languille
 

Company data

Name: Evotec SE
Address: Essener Bogen 7,D-22419 Hamburg
Phone: +49-40-56081-0
Fax: +49-40-56081-222
E-mail: info@evotec.com
Internet: www.evotec.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 62.19%
IPO date: 11/10/1999

Investor relations

Name: Volker Braun
IR phone: +49-40-56081-775
IR Fax: +49-40-56081-222
IR e-mail: InvestorRelations@evotec.com

Company calendar

CW 33 | 8/14/2024 Interim Report 2nd Quarter/6 Months
CW 45 | 11/6/2024 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Others
 
73.00%
T. Rowe Price Group
 
10.00%
Novo Holdings A/S
 
10.00%
Mubadala Investment Company
 
7.00%